Reference
·Primary source
Thailand FDA GMP-certified pharmaceutical facility count (2024)
~180 facilities
Thailand FDA maintains approximately 180 active GMP-certified pharmaceutical manufacturing facilities as of 2024 per Drug Control Division registry, covering small-volume injectables, oral solid dose, sterile manufacturing, biologics fill-finish, and herbal/traditional medicine lines. The certification basis follows PIC/S GMP standards since Thailand's 2016 PIC/S accession, enabling regulatory recognition across PIC/S member jurisdictions. Roughly 25 facilities additionally carry EU GMP cross-certification or US FDA inspection clearance, enabling export to higher-margin regulated markets. The balance serves the domestic market and ASEAN MRA destinations.
Figure in context
Thailand FDA maintains approximately 180 active GMP-certified pharmaceutical manufacturing facilities as of 2024 per Drug Control Division registry, covering small-volume injectables, oral solid dose, sterile manufacturing, biologics fill-finish, and herbal/traditional medicine lines. The certification basis follows PIC/S GMP standards since Thailand's 2016 PIC/S accession, enabling regulatory recognition across PIC/S member jurisdictions. Roughly 25 facilities additionally carry EU GMP cross-certification or US FDA inspection clearance, enabling export to higher-margin regulated markets. The balance serves the domestic market and ASEAN MRA destinations.
Thailand FDA maintains approximately 180 active GMP-certified pharmaceutical manufacturing facilities as of 2024 per Drug Control Division registry, covering small-volume injectables, oral solid dose, sterile manufacturing, biologics fill-finish, and herbal/traditional medicine lines. The certification basis follows PIC/S GMP standards since Thailand's 2016 PIC/S accession, enabling regulatory recognition across PIC/S member jurisdictions. Roughly 25 facilities additionally carry EU GMP cross-certification or US FDA inspection clearance, enabling export to higher-margin regulated markets. The balance serves the domestic market and ASEAN MRA destinations.
Time scope
2024
Source basis
Primary source
Interpretation notes
What this tells you
Thailand FDA maintains approximately 180 active GMP-certified pharmaceutical manufacturing facilities as of 2024 per Drug Control Division registry, covering small-volume injectables, oral solid dose, sterile manufacturing, biologics fill-finish, and herbal/traditional medicine lines. The certification basis follows PIC/S GMP standards since Thailand's 2016 PIC/S accession, enabling regulatory recognition across PIC/S member jurisdictions. Roughly 25 facilities additionally carry EU GMP cross-certification or US FDA inspection clearance, enabling export to higher-margin regulated markets. The balance serves the domestic market and ASEAN MRA destinations.
What not to do with it
Use the linked report for interpretation and keep basis differences explicit.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand pharmaceutical manufacturing factory-gate revenue (2020-2024)
Thai FDA, Pharmaceutical Research and Manufacturers Association of Thailand, Krungsri Research, Bangkok Post pharma coverage
Thailand pharmaceutical generic vs branded mix (2024)
PReMA, IQVIA Thailand, Thai FDA, Government Pharmaceutical Organization
Thailand pharmaceutical manufacturer revenue share (2024)
PReMA, Thai FDA, GPO annual report, Mega Lifesciences, industry estimates
BOI Future Medicine approved projects (2020-2024)
Thailand Board of Investment, BOI Future Medicine sector briefing, NESDC
Siam Bioscience vaccine output capacity (2024)
Siam Bioscience disclosures, PReMA, Bangkok Post pharma coverage, WHO prequalification listing
Thailand pharma facilities with EU GMP cross-certification (2024)
Thai FDA, EudraGMDP database, PReMA, operator disclosures
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.